|April 3, 2017|
|Verastem to Present at the 16th Annual Needham Healthcare Conference|
BOSTON--(BUSINESS WIRE)--Apr. 3, 2017--
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to treat cancer, today announced that the company will present at
the 16th Annual Needham Healthcare Conference on Tuesday,
April 4th at 3:00 p.m. ET at The Westin Grand Central in New
A live audio webcast of the presentation will be available on the
company’s website at www.verastem.com.
An archived presentation will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on
discovering and developing drugs to improve outcomes for patients with
cancer. Verastem is currently developing duvelisib, a dual inhibitor of
phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has
successfully met its primary endpoint in a Phase 2 study in iNHL and is
currently being evaluated in a Phase 3 clinical trial in patients with
chronic lymphocytic leukemia (CLL). In addition, Verastem is developing
the focal adhesion kinase (FAK) inhibitor defactinib, which is currently
being evaluated in three separate clinical collaborations in combination
with immunotherapeutic agents for the treatment of several different
cancer types, including pancreatic cancer, ovarian cancer and non-small
cell lung cancer, and mesothelioma. Verastem’s product candidates seek
to treat cancer by modulating the local tumor microenvironment,
enhancing anti-tumor immunity and reducing cancer stem cells. For more
information, please visit www.verastem.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170403005344/en/
Source: Verastem, Inc.
Brian Sullivan, 781-292-4214